Hims & Hers Health (XSWX:HIMS) YoY EBITDA Growth: -298.31% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:HIMS Hims & Hers Health Inc XSWX:HIMS
78 GF Score
Price CHF23.56
GF Value CHF35.29
! 4 Warning Signs
View Full Analysis

What is Hims & Hers Health YoY EBITDA Growth?

Hims & Hers Health XSWX:HIMS 78 YoY EBITDA Growth is -298.31% as of Jun. 2026. GuruFocus rates XSWX:HIMS with a GF Score™ of 78/100 and a GF Value™ of CHF35.29. The stock has 4 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Hims & Hers Health's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was -298.31%.

Hims & Hers Health's EBITDA per Share for the three months ended in Jun. 2026 was CHF-0.23.

Hims & Hers Health YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Hims & Hers Health's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hims & Hers Health YoY EBITDA Growth Chart

Hims & Hers Health Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial -56.29 48.99 70.61 462.20 66.33

Hims & Hers Health Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 110.71 -2.08 -7.87 -181.86 -298.31
XSWX:HIMS
78GF Score
Hims & Hers Health Inc XSWX:HIMS
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hims & Hers Health YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Hims & Hers Health's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(0.494-0.297)/ | 0.297 |
=66.33 %

Hims & Hers Health's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-0.234-0.118)/ | 0.118 |
=-298.31 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -298.31% mean?
Hims & Hers Health (XSWX:HIMS) has a YoY EBITDA Growth of -298.31% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Hims & Hers Health and its competitors.
Is Hims & Hers Health's YoY EBITDA Growth too high?
Hims & Hers Health's current YoY EBITDA Growth is -298.31%. Overall, Hims & Hers Health has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Hims & Hers Health's YoY EBITDA Growth compare to LNTH and AMRX?
Hims & Hers Health's YoY EBITDA Growth of -298.31% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Hims & Hers Health and its competitors. Hims & Hers Health's current YoY EBITDA Growth is -298.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hims & Hers Health stock overvalued right now?
Hims & Hers Health (XSWX:HIMS) has a current YoY EBITDA Growth of -298.31%. The stock's GF Value™ is CHF35.29, compared to a current price of CHF23.56 — trading 33.3% below its estimated fair value. The current YoY EBITDA Growth is -298.31%. Hims & Hers Health's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Hims & Hers Health (XSWX:HIMS), the current YoY EBITDA Growth is -298.31% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hims & Hers Health (XSWX:HIMS) Overvalued in 2026?

Based on GuruFocus' analysis, Hims & Hers Health stock appears to be undervalued. The current stock price of CHF23.56 is trading 33.3% below its estimated GF Value™ of CHF35.29.

Key valuation signals for XSWX:HIMS:

  • YoY EBITDA Growth: -298.31%
  • GF Value™: CHF35.29 vs. price of CHF23.56 (33.3% below fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the XSWX:HIMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hims & Hers Health Business Description

Address 2269 Chestnut Street, No. 523, San Francisco, CA, USA, 94123
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
78GF Score

Get the complete analysis for XSWX:HIMS

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF23.56
Price
CHF35.29
GF Value